News|Articles|November 16, 2026

FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM

Fact checked by: Patrick Campbell

Key Takeaways

  • FDA labeling now includes head-to-head MAPLE-HCM evidence versus metoprolol, supporting aficamten as a potential first-line monotherapy option and providing payer-relevant justification beyond background-therapy trials.
  • MAPLE-HCM randomized 175 symptomatic oHCM patients to titrated aficamten (5–20 mg) or metoprolol (50–200 mg) for 24 weeks, with baseline LVOT gradients 47 mm Hg rest/74 mm Hg Valsalva.
SHOW MORE

The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) adding data from the phase 3 MAPLE-HCM trial to the US Prescribing Information for aficamten (Myqorzo), a cardiac myosin inhibitor (CMI) indicated to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1

Cytokinetics announced the label update on November 16, 2026. The indication itself is unchanged. With the update, Cytokinetics says aficamten is the only cardiac myosin inhibitor carrying label data comparing its effectiveness with a beta-blocker.1

Frequently Asked Questions

What is aficamten approved for?

Aficamten (Myqorzo) is approved in the US to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy. The MAPLE-HCM label update adds comparative data but does not change the indication.

How does aficamten work?

Aficamten is a cardiac myosin inhibitor which reduces cardiac contractility, lowering LVOT obstruction. Cytokinetics designed it for predictable exposure-response, rapid onset, and reversibility.

What did the MAPLE-HCM trial show?

As monotherapy, aficamten improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks (P < .001). It also significantly improved five of six secondary endpoints, including NYHA class, KCCQ-CSS, and NT-proBNP.

Beta-blockers have served as initial therapy for symptomatic oHCM despite limited evidence of their efficacy. The FDA originally approved aficamten in December 2025 on the basis of SEQUOIA-HCM, a placebo-controlled phase 3 trial in patients receiving background therapy.1,2

Ahmad Masri, MD, MS, director of the Hypertrophic Cardiomyopathy Center and Cardiac Amyloidosis Program at Oregon Health & Science University and co-author on MAPLE-HCM, sat down with HCPLive to discuss what this update means for clinicians and patients alike.

“MAPLE-HCM has been out there for quite some time, but that doesn’t mean that clinically you can jump to using a CMI like aficamten. You can, but a lot of the time the payers will tell you no,” Masri told HCPLive in an exclusive interview. “Having a label update that says that aficamten is an acceptable option for upfront first-line monotherapy is quite a substantial improvement on what we have right now.”

MAPLE-HCM was a multicenter, randomized, double-blind, double-dummy trial comparing aficamten monotherapy with metoprolol monotherapy in adults with symptomatic oHCM. Investigators randomized 175 patients 1:1 to aficamten titrated from 5 mg to 20 mg daily (n = 88) or metoprolol titrated from 50 mg to 200 mg daily (n = 87), each with a matching placebo, for 24 weeks. At baseline, mean age was 58 years, 58.3% of patients were men, and mean left ventricular outflow tract (LVOT) gradients were 47 mm Hg at rest and 74 mm Hg after the Valsalva maneuver.1,2

Aficamten met the primary endpoint of change in peak oxygen uptake (pVO2) from baseline to week 24. Peak VO2 increased by 1.1 mL/kg/min (95% CI, 0.5–1.7) with aficamten and decreased by 1.2 mL/kg/min (95% CI, −1.7 to −0.8) with metoprolol, a least-squares mean between-group difference of 2.3 mL/kg/min (95% CI, 1.5–3.1; P <.001).1,2

According to Cytokinetics, the pVO2 benefit was consistent across all prespecified subgroups, including newly diagnosed and treatment-naive patients.1

Aficamten secondary endpoints and safety in obstructive HCM

Aficamten significantly improved five of six secondary endpoints compared with metoprolol, per the company. Patients receiving aficamten had greater improvements in New York Heart Association (NYHA) functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), post-Valsalva LVOT gradient, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and left atrial volume index (LAVI). Left ventricular mass index did not differ significantly between groups.1,2

In an echocardiographic analysis of MAPLE-HCM, aficamten reduced the Valsalva LVOT gradient by 35 mm Hg (95% CI, −44 to −26; P <.001) and LAVI by 7.0 mL/m2 (95% CI, −9.1 to −4.8; P <.001) relative to metoprolol. Left ventricular ejection fraction (LVEF) declined by 4% (95% CI, −5% to −3%; P <.001) with aficamten vs metoprolol, with no significant between-group difference in resting cardiac output.3

Overall adverse event rates were similar between arms. Hypertension was the most common adverse reaction occurring more often with aficamten (15% vs 3% with metoprolol), while dizziness was the most frequent excess event in the metoprolol arm. In SEQUOIA-HCM, hypertension occurred in 8% of aficamten-treated patients vs 2% of those receiving placebo.1

Aficamten boxed warning, REMS, and drug interactions

Aficamten carries a boxed warning for heart failure due to systolic dysfunction, and echocardiographic LVEF assessment is required before and during treatment. Initiation is not recommended at an LVEF below 55%; the dose should be reduced at an LVEF of 40% to below 50% and interrupted below 40% or with heart failure symptoms or worsening clinical status. The drug is available only through the Myqorzo REMS program, which requires certification of prescribers and pharmacies and enrollment of patients.1

Concomitant rifampin is contraindicated. Aficamten is metabolized primarily by CYP2C9, with lesser contributions from CYP3A, CYP2D6, and CYP2C19. LVEF should be reassessed two to eight weeks after starting or stopping interacting agents, with dose adjustment as needed.1

“For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” Robert Blum, president and chief executive officer of Cytokinetics, said in a statement. “Myqorzo is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its US label, providing cardiologists and patients important information to inform treatment decisions.”1

Cytokinetics plans to submit an sNDA in the fourth quarter of 2026 for aficamten in nonobstructive HCM based on the phase 3 ACACIA-HCM trial. The pediatric CEDAR-HCM study and the FOREST-HCM open-label extension are ongoing, and aficamten is also approved for oHCM in China, the European Union, the United Kingdom, and Canada.1

References
  1. Cytokinetics. Cytokinetics announces prescribing information for Myqorzo (aficamten) expanded to include data from phase 3 MAPLE-HCM. Published November 16, 2026. Accessed November 16, 2026. https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Prescribing-Information-for-MYQORZO-aficamten-Expanded-to-Include-Data-from-Phase-3-MAPLE-HCM/default.aspx
  2. Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy. N Engl J Med. 2025;393(10):949-960. doi:10.1056/NEJMoa2504654
  3. Hegde SM, Wang X, Garcia-Pavia P, et al. Effect of aficamten compared with metoprolol on echocardiographic measures in symptomatic obstructive hypertrophic cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. 2025;86(24):2452-2467. doi:10.1016/j.jacc.2025.08.022

Related to this article